Trump’s Orders Elevate The Medical Status Of Psychedelics And Cannabis – Forbes
Federal policy changes around cannabis and psychedelics create significant federal cannabis rescheduling clinical implications for medical practice. Understanding regulatory shifts helps clinicians navigate evolving treatment landscapes while maintaining…
The Trump administration’s moves on marijuana and psychedelics signal the start of a new …
✦ New CED Clinical Relevance #55 Clinical Context Background information relevant to the evolving cannabis medicine landscape. PolicyResearchMental Health Clinical Summary I don’t have access to the full article content needed to write an…
Classic psychedelic and cannabis use among U.S. cancer survivors aged ≥ 50 years: nationally representative estimates by cancer type/site.
To examine the prevalence of lifetime ("ever") cannabis and classic psychedelic use, and their co-use among U.S. adults aged ≥ 50 years with versus without a...
Brain-Body Integromics of the Ayahuasca Experience
Brain-body integration ayahuasca effects reveal how this psychoactive brew induces coordinated changes across biological systems. This study maps metabolism, brain connectivity, and subjective experience in ayahuasca users. Understanding these effects is…
Amrit Baral: Cannabis and Psychedelic Use Among Older U.S. Cancer Survivors
Psychedelic use older cancer survivors is an emerging area of clinical interest. This article provides estimates that inform screening and safety considerations. Understanding these patterns helps optimize symptom management in older cancer survivors.
Trump’s Psychedelic Executive Order: Symbolic Impact Analyzed
The psychedelic executive order impact is largely symbolic but influences research funding and regulatory pathways. Analysts note limited immediate regulatory changes, yet the order signals federal support for psychedelic medicine research. This policy…
Why Veterans Advocate for Looser Psychedelic and Cannabis Research Restrictions
Veterans psychedelic cannabis research highlights the need for looser restrictions to advance treatment options. This research focuses on PTSD and treatment-resistant conditions common among veterans. Looser research restrictions could enable better…
Joshua S. Bauchner Discusses Psychedelics Policy at Cannabis Research Conference
This article highlights psychedelics policy developments 2026 and their implications for clinical access. Cross-pollination between cannabis and psychedelic policies signals regulatory convergence. Clinicians should monitor these developments as they…
Classic psychedelic and cannabis use among U.S. cancer survivors aged ≥ 50 years: nationally representative estimates by cancer type/site.
This study examines classic psychedelic and cannabis use among older cancer survivors aged 50 years and above. It provides nationally representative estimates by cancer type and site. Understanding these patterns is crucial for clinical and policy…
Analyzing Trump’s Psychedelic Executive Order: Clinical Insights
This article provides a focused psychedelic executive order analysis highlighting its clinical impact. It examines how regulatory changes influence research and patient treatment access. Clinicians are encouraged to review policy details to understand…